Who Will You Meet at the 4th Cell Therapy for Autoimmune Disease Summit?
The Companies Defining the Future of Immune Reset
As autoimmune cell therapy enters a new phase of clinical maturity, the conversation is expanding beyond proof-of-concept and into questions of durability, safety, scalability, manufacturing readiness, and commercialization.
The 4th Cell Therapy for Autoimmune Disease Summit brings together the biotech, pharma, academic, investor, and solution provider communities responsible for advancing these therapies from early development through to clinical and commercial reality.
Whether you are developing a CAR-T, CAR-NK, Treg, MSC, allogeneic, autologous, or in vivo program, this is where you'll find the teams actively tackling the scientific and strategic challenges shaping the field.
The summit offers the opportunity to connect with organizations generating clinical and translational data across autoimmune indications, evaluating next-generation targets, and defining what immune reset looks like in practice.
Companies Attending Include:
Engage With Decision Makers Across the Development Lifecycle
The audience extends far beyond researchers alone.
Attendees include leaders responsible for:
Clinical development
Translational medicine
Immunology
Autoimmune disease research
Cell therapy discovery
Manufacturing and CMC
R&D strategy
Clinical operations
Business development
External innovation
Scientific alliances
Investment and portfolio strategy
Recent registrations include Chief Medical Officers, Chief Scientific Officers, CEOs, Presidents, Vice Presidents, Directors, Principal Scientists, Clinical Operations leaders, Translational Medicine experts, and Business Development teams.
Benchmark Against Organizations Solving Similar Challenges
The autoimmune cell therapy field is moving quickly. Teams are evaluating new targets, refining immune reset strategies, exploring in vivo approaches, and preparing therapies for larger patient populations.
By attending, you'll have the opportunity to engage with companies actively working on:
Immune Reset & Durability
- Understanding immune reconstitution
- Defining biomarkers of response
- Building durable remission strategies
- Measuring long-term outcomes
Emerging Modalities
- Autologous CAR-T
- Allogeneic cell therapy
- CAR-NK
- Treg therapies
- MSC therapies
- In vivo cell engineering
Scaling for Commercial Reality
- Manufacturing readiness
- Patient selection
- Community adoption
- Pricing and reimbursement
- Global development strategies
For Solution Providers, it is a Prime Opportunity to Understand Where Developer Needs Are Headed Next
As autoimmune cell therapy programs mature, demand continues to increase for specialist expertise across development, manufacturing, analytics, and commercialization.
The summit attracts teams responsible for:
Cell Therapy Manufacturing
Analytical Testing
Clinical Operations
Translational Services
Biomarker Development
Regulatory Strategy
Supply Chain and Logistics
Platform Technologies
Current sponsors and attending solution providers include organizations such as MaxCyte, Biocytogen, Allucent, American Red Cross, and Kytopen, alongside developers actively evaluating future partnerships.
Rather than meeting prospects after programs are fully established, this audience provides an opportunity to build relationships with companies making strategic development decisions today.
A Truly Cross-Functional Audience
One of the defining characteristics of the summit is the mix of scientific, clinical, and commercial expertise represented in one place.
Attendee Functions Include:
Research & Discovery
- Immunology
- Autoimmunity
- Discovery Biology
- Translational Science
Clinical Development
- Clinical Operations
- Medical Affairs
- Patient Safety
- Trial Design
Leadership
- CEO
- CSO
- CMO
- President
- Vice President
Commercial & Strategy
- Business Development
- Strategic Alliances
- Corporate Strategy
- Investment
This creates opportunities to benchmark decisions across the entire development lifecycle rather than within a single function.
Audience Composition Overview:
